Baxter Announces Primary Efficacy Endpoint for Phase 3 Trial of BAX 11 Was Met, Will File for Approval in US Before End of '14
April 16, 2014 at 08:50 AM EDT
Baxter International Inc. (NYSE: BAX) today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and ...
